Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sfj Pharmaceuticals Inc.
Headquarters: Pleasanton, CA, United States of America
Website: http://www.sfj-pharma.com
Year Founded: 2008
Status: Private
BioCentury | Sep 10, 2024
Management Tracks
Vir names Jason O’Byrne CFO
Plus: Maslowski to become CEO of Forge as Miller steps down, and updates from Sofinnova Partners, Abingworth, PATH and more
BioCentury | Oct 30, 2023
Finance
New $356M fund gives Abingworth more cash for late-stage trials
With some biopharmas strapped for cash to fund Phase III programs, PE-backed firm’s co-investment fund now supplements co-development fund
BioCentury | May 13, 2023
Deals
May 12 Quick Takes: AZ latest pharma to gain rights to a LaNova ADC
Plus: FDA clears Astellas’ therapy for hot flashes updates from Cullgen and SFJ-Serb
BioCentury | Jan 18, 2023
Finance
Carlyle, Abingworth again testing Launch model with Pathalys’ kidney disease asset
Leading $150M round, PE-backed venture firm will draw on clinical expertise of organization set up to advise on late-stage trials
BioCentury | Aug 19, 2022
Finance
Carlyle, Abingworth back Opthea’s AMD ambitions in largest-ever Australian deal
First risk-sharing investment since VC’s takeout will position strategic entity Launch to advise Australian biotech as it navigates Phase III with up to $260M
BioCentury | Apr 11, 2022
Deals
Via Abingworth takeout, Carlyle gains biotech skill set
Ending a 49-year run as an independent firm, Abingworth will gain Carlyle’s resources to invest in expensive co-development programs
BioCentury | Mar 14, 2022
Product Development
Nektar facing reorg after BMS-partnered program’s melanoma failure
Four years after BMS paid nearly $1.9B up front to share IL-2 program’s rights, Phase III failure leaves Nektar at a crossroads
BioCentury | Dec 16, 2021
Finance
Dec. 15 Quick Takes: Mythic Raises $103M series B
Plus: JPM goes virtual, Genenta’s IPO and updates from Travere, Boehringer, Sobi-Apellis, J&J, Calliditas and more
BioCentury | Oct 16, 2021
Data Byte
CHMP opinions for October
Trodelvy, Rybrevant among the recommended
BioCentury | May 15, 2021
Deals
May 14 Quick Takes: With PNH approval, Apellis’ development partner due for payouts; plus Vera, Kinnate, Nephraegis, Shifa, Grove and more
Now that FDA has approved Empaveli pegcetacoplan from Apellis Pharmaceuticals Inc. (NASDAQ:APLS) to treat paroxysmal nocturnal hemoglobinuria, the risk-sharing entity that funded Empaveli’s
Items per page:
1 - 10 of 89